--\> This is a substudy of the main ESTxENDS trial (NCT03589989). Oxidative stress outcomes should be considered secondary outcomes of the main smoking cessation outcome formulated in NCT03589989. Cigarette smoking is the leading cause of preventable death in Switzerland and still more than a quarter of the Swiss population smokes cigarettes. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer or electronic cigarette) have become popular with smokers who want to stop smoking or reduce their exposure to inhaled chemicals since ENDS use appears to be safer than tobacco smoking. Smoking induces inflammation leading to acute and chronic oxidative stress, both evidenced in in vitro and in vivo studies. Tobacco-smoke contains free reactive radicals that generate reactive oxygen species (ROS). Afterwards ROS in turn induce oxidative stress, which likely plays a key role in causing airways and related pathologies linked to tobacco-smoke exposure. Acute and chronic oxidative stress can be measured by quantifying two biomarkers in urine samples: 8-iso-prostaglandin F2α (8-isoprostane) and 8-Oxo-2'-deoxyguanosine (8-OHdG). 8-isoprostane, a marker of lipoperoxidation, results mainly from the non-enzymatic action of free radical attack on arachidonic fatty acids. 8-OHdG is a marker of DNA oxidation caused by ROS, and a predictor of lung cancer. Oxidative stress between smokers who quit (with or without ENDS) and those who use ENDS for a long time have not yet been assessed in the setting of a randomized controlled trial (RCT). This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the safety of ENDS on adverse events, the exposure to inhaled chemicals and the effect of ENDS on health-related outcomes, in particular by measuring oxidative stress in urine samples. For the main ESTxENDS trial (NCT03589989), cigarette smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants in the control group will receive smoking cessation counseling only. All participants will be followed over a 24-month period. Measures of oxidative stress by means of exhaled breath condensates and urine samples will be assessed at baseline and at 6-, 12- and 24- months' follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,246
Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne
Lausanne, Canton of Vaud, Switzerland
University Clinic for General Internal Medicine, Bern University Hospital
Bern, Switzerland
Département de médecine interne, Hôpitaux universitaires de Genève
Geneva, Switzerland
Lungenzentrum, Klinik für Pneumologie und Schlafmedizin, Kantonsspital St. Gallen
Sankt Gallen, Switzerland
Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich
Zurich, Switzerland
Urinary 8-OHdG concentrations to asses oxidative stress_1
Oxidative stress assessed by 8-OHdG concentrations in urine.
Time frame: 6 months post quit date
Urinary 8-OHdG concentrations to asses oxidative stress_2
Oxidative stress assessed by 8-OHdG concentrations in urine.
Time frame: 12 months post quit date
Urinary 8-OHdG concentrations to asses oxidative stress_3
Oxidative stress assessed by 8-OHdG concentrations in urine.
Time frame: 24 months post quit date
Urinary 8-isoprostane concentrations to asses oxidative stress_1
Oxidative stress assessed by 8-isoprostane concentrations in urine.
Time frame: 6 months post quit date
Urinary 8-isoprostane concentrations to asses oxidative stress_2
Oxidative stress assessed by 8-isoprostane concentrations in urine.
Time frame: 12 months post quit date
Urinary 8-isoprostane concentrations to asses oxidative stress_3
Oxidative stress assessed by 8-isoprostane concentrations in urine.
Time frame: 24 months post quit date
Change in urinary 8-OHdG concentrations to asses oxidative stress
Oxidative stress assessed by 8-OHdG concentrations in urine.
Time frame: Change from baseline to 6,12, 24 months post quit date
Change in urinary 8-isoprostane concentrations to asses oxidative stress
Oxidative stress assessed by 8-isoprostane concentrations in urine.
Time frame: Change from baseline to 6,12, 24 months post quit date
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.